Treatment of cognitive impairment in early psychosis: A comparison of risperidone and haloperidol in a large long-term trial

American Journal of Psychiatry

Volumn 162, Issue 10, 2005, Pages 1888-1895

  Harvey, Philip D ^a   Rabinowitz, Jonathan ^a   Eerdekens, Marielle ^a   Davidson, Michael ^a  

^a BAR ILAN UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; RISPERIDONE;

ADULT; ALERTNESS; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; VERBAL MEMORY; VISUOMOTOR COORDINATION;

ADULT; AGE OF ONSET; ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HALOPERIDOL; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TIME FACTORS; TREATMENT OUTCOME;

EID: 17444362717     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.162.10.1888     Document Type: Article

References (40)

1. Elvevag B, Goldberg TE: Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol 2000; 14:1-21
2. Cornblatt BA, Keilp JG: Impaired attention, genetics, and the pathophysiology of schizophrenia. Schizophr Bull 1994; 20:31-46
3. Gold JM, Carpenter C, Randolph C, Goldberg TE, Weinberger DR: Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia. Arch Gen Psychiatry 1997; 54:159-165
4. Saykin AJ, Gur RC, Gur RE, Mozley PD, Mozley LH, Resnick SM, Kester DB, Stafiniak P: Neuropsychological function in schizophrenia: selective impairment in memory and learning. Arch Gen Psychiatry 1991; 48:618-624
5. Gourovitch M, Goldberg T, Weinberger D: Verbal fluency deficits in patients with schizophrenia: semantic fluency is differentially impaired as compared to phonological fluency. Neuropsychology 1996; 6:573-577
6. Gold JM, Goldberg RW, McNary SW, Dixon LB, Lehman AF: Cognitive correlates of job tenure among patients with severe mental illness. Am J Psychiatry 2002; 159:1395-1402
7. Saykin AJ, Shtasel DL, Gur RE, Kester DB, Mozley LH, Stafiniak P, Gur RC: Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry 1994; 51:124-131
8. Davidson M, Reichenberg A, Rabinowitz J, Weiser M, Kaplan Z, Mark M: Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents. Am J Psychiatry 1999; 156:1328-1335
9. Rabinowitz J, Reichenberg A, Weiser M, Mark M, Kaplan Z, Davidson M: Cognitive and personality functioning during the decade prior to first hospitalization and early course of psychotic illness. Br J Psychiatry 2000; 177:26-32
10. Green MF, Kern RS, Braff DL, Mintz J: Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull 2000; 26:119-136
11. Harvey PD, Howanitz E, Parrella M, White L, Davidson M, Mohs RC, Hoblyn J, Davis KL: Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. Am J Psychiatry 1998; 155:1080-1086
12. Harvey PD, Green MF, Keefe RS, Velligan DI: Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. J Clin Psychiatry 2004; 65:361-372
13. Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G: One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 1994; 151:1409-1416
14. Ho B-C, Andreasen N, Flaum M: Dependence on public financial support early in the course of schizophrenia. Psychiatr Serv 1997; 48:948-950
15. Keefe RS, Silva SG, Perkins DO, Lieberman JA: The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 1999; 25:201-222
16. Harvey PD, Keefe RSE: Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 2001; 158:176-184
17. Keefe RSE, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, Lewine RRJ, Yurgelun-Todd DA, Gur RC, Tohen M, Tollefson GD, Sanger TM, Lieberman JA (HGDH Research Group): Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry 2004; 161:985-995
18. Harvey PD, Green MF, McGurk SR, Meltzer HY: Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. Psychopharmacology (Berl) 2003; 169:404-411
19. Harvey PD, Siu CO, Romano S: Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Psychopharmacology (Berl) 2004; 172:324-332
20. Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, Lindenmayer J-P, Citrome L, McEvoy J, Kunz M, Chakos M, Cooper TB, Horowitz TL, Lieberman JA: Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002; 159:1018-1028
21. Harvey PD, Napolitano JA, Mao L, Gharabawi G: Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder. Int J Geriatr Psychiatry 2003; 18:820-829
22. Green MF, Marder SR, Glynn SM, McGurk SR, Wirshing WC, Wirshing DA, Liberman RP, Mintz J: The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol Psychiatry 2002; 51:972-978
23. Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey PD, Kopala L, McGorry PD, Van Hove I, Eerdekens M, Swyzen W, De Smedt G (Early Psychosis Global Working Group): Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry 2005; 162:947-953
24. Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261-276
25. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Rockville, Md, US Department of Health, Education, and Welfare, 1976, pp 217-222
26. Harvey PD, Artiola i Fortuny L, Vester-Blockland E, De Smedt G: Cross-national cognitive assessment in schizophrenia clinical trials: a feasibility study. Schizophr Res 2003; 59:243-251
27. Wechsler D: The Wechsler Memory Scale - Revised. San Antonio, Tex, Psychological Corp, 1987
28. Spreen O, Strauss E: A Compendium of Neuropsychological Tests and Norms. New York, Oxford University Press, 1998
29. Cornblatt BA, Lenzenweger MF, Erlenmeyer-Kimling L: The Continuous Performance Test, Identical Pairs Version, II: contrasting attentional profiles in schizophrenic and depressed patients. Psychiatry Res 1989; 29:65-85
30. Gladsjo JA, Schuman CC, Evans JD, Peavy GM, Miller SW, Heaton RK: Norms for letter and category fluency: demographic corrections for age, education, and ethnicity. Assessment 1999; 6:147-178
31. Wechsler D: The Wechsler Adult Intelligence Scale - Revised. New York, Psychological Corp, 1978
32. Heaton RK, Chelune GJ, Talley JL, Kay GG, Curtiss G: Wisconsin Card Sorting Test Manual. Odessa, Fla, Psychological Assessment Resources, 1993
33. Purdon SE, Jones BD, Stip E, Labelle A, Addington D, David SR, Breier A, Tollefson GD (Canadian Collaborative Group for Research in Schizophrenia): Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch Gen Psychiatry 2000; 57:249-258
34. Robinson DG, Woerner MG, Alvir JMJ, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Bilder R, Goldman R, Lieberman JA: Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999; 156:544-549
35. Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Lieberman JA: Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999; 56:241-247
36. Robinson DG, Woerner MG, Alvir JM, Bilder RM, Hinrichsen GA, Lieberman JA: Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr Res 2002; 57:209-219
37. Robinson DG, Woerner MG, McMeniman M, Mendelowitz A, Bilder RM: Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 2004; 161:473-479
38. Bilder RM, Goldman RS, Robinson D, Reiter G, Bell L, Bates JA, Pappadopulos E, Willson DF, Alvir JMJ, Woerner MG, Geisler S, Kane JM, Lieberman JA: Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry 2000; 157:549-559
39. Rabinowitz J, Bromet E, Davidson M: Are patients enrolled in first episode psychosis drug trials representative of those treated in routine clinical practice? Schizophr Res 2003; 61:149-155
40. McGurk SR, Meltzer HY: The role of cognition in vocational functioning in schizophrenia. Schizophr Res 2000; 45:175-184